Health & Biotech
ASX Health Stocks: Recce, Cynata say their diabetic foot ulcer trials are going great guns
Health & Biotech
Regal cornerstones $14m CardieX raise as medtech prepares to debut world-first vascular biometric monitor
Health & Biotech
Q+A: Dimerix CEO on upcoming milestone Phase III interim trial results
Health & Biotech
ScoPo’s Powerplays: ASX health stocks flat in ‘up and down’ reporting season
Health & Biotech
ASX Health Stocks: Rural vet stock Apiam jumps 17pc on huge first half
Health & Biotech
These ASX biotechs want to tackle cancer head-on for better outcomes
Health & Biotech
ASX Health Stocks: Cogstate falls as pipeline contracts; LBT delivers product to Thermo Fisher
Health & Biotech
PharmAust forms scientific advisory board to guide next phase of monepantel for treatment of MND/ALS
Health & Biotech
Diagnosing mental disorder through sleep: How TrivarX could capture this huge research market
Health & Biotech
Weed Week: Iron Mike throws down challenge to Biden, and recent ASX pot winners
Health & Biotech
‘Significant potential’: This ASX stock is winning the race to make cancer care heart-safe
Health & Biotech
Neurotech reports sustained clinical progress in PANDAS/PANS patients during Phase I/II extension study
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.